New Drug Combo Significantly Reduces Breast Cancer Progression Risk
TL;DR Summary
A Phase 3 study shows that combining Gilead's Trodelvy with Merck's Keytruda significantly reduces tumor progression risk in women with aggressive triple-negative breast cancer, potentially leading to new treatment options.
- Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows statnews.com
- Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Reuters
- ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC OncLive
- ASCO: Gilead bolsters Trodelvy in triple-negative breast cancer with practice-changing Keytruda combo win Fierce Pharma
- Blockbuster breast cancer drug combination will change the way cancer is treated New York Post
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
90%
287 → 30 words
Want the full story? Read the original article
Read on statnews.com